{"log_id": 4624067226557803418, "direction": 0, "words_result_num": 27, "words_result": [{"probability": {"variance": 2e-06, "average": 0.998464, "min": 0.994964}, "location": {"width": 202, "top": 298, "height": 31, "left": 213}, "words": "【药物相互作用】"}, {"probability": {"variance": 4e-06, "average": 0.998532, "min": 0.989575}, "location": {"width": 836, "top": 344, "height": 38, "left": 251}, "words": "本品主要经CYP3A代谢(参见【药代动力学】)。因此,这些酶类的抑制剂或诱"}, {"probability": {"variance": 1e-06, "average": 0.999394, "min": 0.997221}, "location": {"width": 327, "top": 397, "height": 30, "left": 204}, "words": "导剂可能改变本品的药代动力学"}, {"probability": {"variance": 0.002597, "average": 0.98798, "min": 0.680583}, "location": {"width": 834, "top": 438, "height": 34, "left": 252}, "words": "本品与已知CYP3A4抑制剂(例如,酮康唑,伊曲康唑或葡萄柚汁)同时给药时应"}, {"probability": {"variance": 1e-06, "average": 0.999475, "min": 0.995145}, "location": {"width": 884, "top": 482, "height": 37, "left": 204}, "words": "谨慎,并且应严密监测临床反应和不良事件(参见【注意事项】)。但如果患者必须"}, {"probability": {"variance": 1.5e-05, "average": 0.997961, "min": 0.980801}, "location": {"width": 882, "top": 529, "height": 35, "left": 205}, "words": "合并使用CYP3A4强抑制剂,根据药代动力学研究,预计本品剂量减至500mg/天可将本"}, {"probability": {"variance": 7.1e-05, "average": 0.997191, "min": 0.947129}, "location": {"width": 884, "top": 574, "height": 36, "left": 205}, "words": "品AUC调整至无抑制剂时的范围。但接受CYP3A4强抑制剂的患者中,这一剂量调整方"}, {"probability": {"variance": 2e-06, "average": 0.999148, "min": 0.990229}, "location": {"width": 882, "top": 621, "height": 35, "left": 205}, "words": "案没有相关临床数据支持。如果停用强抑制剂,在本品剂量上调至指定剂量前应当有"}, {"probability": {"variance": 3e-05, "average": 0.996238, "min": 0.982294}, "location": {"width": 191, "top": 672, "height": 29, "left": 205}, "words": "大约1周的洗脱期"}, {"probability": {"variance": 0.000247, "average": 0.993482, "min": 0.924636}, "location": {"width": 837, "top": 712, "height": 35, "left": 252}, "words": "本品与已知CYP3A4诱导剂(例如,利福平,卡马西平或苯妥英)同时给药时应谨"}, {"probability": {"variance": 0.002412, "average": 0.987374, "min": 0.757344}, "location": {"width": 882, "top": 757, "height": 36, "left": 205}, "words": "慎,并且应仔细监测临床反应和不良事件(参见【注意事项】)。如果患者必须同时"}, {"probability": {"variance": 0.000319, "average": 0.994692, "min": 0.89001}, "location": {"width": 886, "top": 803, "height": 33, "left": 206}, "words": "服用强效CYP3A4诱导剂,基于药代动力学研究,应根据耐受性,将本品的剂量从1250"}, {"probability": {"variance": 0.002115, "average": 0.985616, "min": 0.759825}, "location": {"width": 882, "top": 850, "height": 32, "left": 208}, "words": "mg/天逐步增加至4500mg/天。预计本品这一剂量可使本品AUC调整至无诱导剂时的范"}, {"probability": {"variance": 0.0001, "average": 0.996593, "min": 0.937493}, "location": {"width": 884, "top": 895, "height": 34, "left": 207}, "words": "围内。接受CYP3A4强诱导剂的患者中,这一剂量调整方案没有相关临床数据支持。如"}, {"probability": {"variance": 1e-06, "average": 0.999194, "min": 0.994912}, "location": {"width": 632, "top": 941, "height": 34, "left": 206}, "words": "果停用强诱导剂,应当在超过2周时间本品逐步降至指定剂量"}, {"probability": {"variance": 0.000991, "average": 0.991656, "min": 0.830058}, "location": {"width": 838, "top": 987, "height": 31, "left": 253}, "words": "在本品使用前应用质子泵抑制剂(奥美拉唑)治疗,平均降低本品暴露27%(范"}, {"probability": {"variance": 2.9e-05, "average": 0.997692, "min": 0.974045}, "location": {"width": 884, "top": 1031, "height": 34, "left": 207}, "words": "围:6%至49%)。该效应随着年龄升高(大约40岁至60岁)而降低。在前期使用过"}, {"probability": {"variance": 1e-06, "average": 0.999216, "min": 0.996898}, "location": {"width": 471, "top": 1078, "height": 34, "left": 206}, "words": "质子泵抑制剂治疗的患者中使用本品时应谨慎"}, {"probability": {"variance": 0.000113, "average": 0.996589, "min": 0.933551}, "location": {"width": 837, "top": 1122, "height": 35, "left": 254}, "words": "本品在临床有效浓度下体外可抑制CYP3A4。本品与口服咪达唑仑的同时给药导致"}, {"probability": {"variance": 0.000191, "average": 0.994297, "min": 0.920721}, "location": {"width": 885, "top": 1169, "height": 33, "left": 207}, "words": "咪达唑仑的AUC增加约45%。咪达唑仑静脉给药时AUC的升高无临床意义。本品应当避"}, {"probability": {"variance": 1.2e-05, "average": 0.997901, "min": 0.986215}, "location": {"width": 621, "top": 1215, "height": 34, "left": 208}, "words": "免与属于CYP3A4底物的治疗窗比较窄的口服药物合用(参见"}, {"probability": {"variance": 2.2e-05, "average": 0.995147, "min": 0.987774}, "location": {"width": 82, "top": 1216, "height": 23, "left": 923}, "words": "力学】)"}, {"probability": {"variance": 0.001106, "average": 0.985614, "min": 0.868354}, "location": {"width": 841, "top": 1252, "height": 63, "left": 255}, "words": "本品在临床有效浓度下体外可抑制CYP2C8。本品应与底物的治"}, {"probability": {"variance": 0.016646, "average": 0.942112, "min": 0.583335}, "location": {"width": 779, "top": 1300, "height": 66, "left": 206}, "words": "疗窗比较窄的药物(为CYP2C8的底物)同时给予,如果过医药限公司"}, {"probability": {"variance": 0, "average": 0.999869, "min": 0.999768}, "location": {"width": 97, "top": 1305, "height": 28, "left": 996}, "words": "【药"}, {"probability": {"variance": 2.2e-05, "average": 0.997141, "min": 0.986583}, "location": {"width": 132, "top": 1355, "height": 28, "left": 211}, "words": "代动力学】)"}, {"probability": {"variance": 0.047509, "average": 0.701477, "min": 0.35084}, "location": {"width": 103, "top": 1336, "height": 68, "left": 818}, "words": "NH米"}], "language": 3}